Laronidase + Cyclosporine A (CsA) + Azathioprine (Aza)
Phase 1/2Completed 0 watching 0 views this week⚡ Active
40
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mucopolysaccharidosis I
Conditions
Mucopolysaccharidosis I
Trial Timeline
Sep 1, 2008 → Sep 1, 2012
NCT ID
NCT00741338About Laronidase + Cyclosporine A (CsA) + Azathioprine (Aza)
Laronidase + Cyclosporine A (CsA) + Azathioprine (Aza) is a phase 1/2 stage product being developed by Sanofi for Mucopolysaccharidosis I. The current trial status is completed. This product is registered under clinical trial identifier NCT00741338. Target conditions include Mucopolysaccharidosis I.
Hype Score Breakdown
Clinical
13
Activity
8
Company
9
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00741338 | Phase 1/2 | Completed |
Competing Products
20 competing products in Mucopolysaccharidosis I